Bristol-Myers Squibb Co
NYSE:BMY
Intrinsic Value
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. [ Read More ]
The intrinsic value of one BMY stock under the Base Case scenario is 74.86 USD. Compared to the current market price of 48.79 USD, Bristol-Myers Squibb Co is Undervalued by 35%.
Valuation Backtest
Bristol-Myers Squibb Co
Run backtest to discover the historical profit from buying and selling BMY stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Bristol-Myers Squibb Co
Current Assets | 31.8B |
Cash & Short-Term Investments | 12.3B |
Receivables | 15.3B |
Other Current Assets | 4.2B |
Non-Current Assets | 63.4B |
Long-Term Investments | 2.1B |
PP&E | 8B |
Intangibles | 48.2B |
Other Non-Current Assets | 5B |
Current Liabilities | 22.3B |
Accounts Payable | 3.3B |
Accrued Liabilities | 11.2B |
Short-Term Debt | 246m |
Other Current Liabilities | 7.6B |
Non-Current Liabilities | 43.5B |
Long-Term Debt | 36.7B |
Other Non-Current Liabilities | 6.8B |
Earnings Waterfall
Bristol-Myers Squibb Co
Revenue
|
45B
USD
|
Cost of Revenue
|
-10.6B
USD
|
Gross Profit
|
34.4B
USD
|
Operating Expenses
|
-23.6B
USD
|
Operating Income
|
10.8B
USD
|
Other Expenses
|
-2.8B
USD
|
Net Income
|
8B
USD
|
Free Cash Flow Analysis
Bristol-Myers Squibb Co
BMY Profitability Score
Profitability Due Diligence
Bristol-Myers Squibb Co's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
Score
Bristol-Myers Squibb Co's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
BMY Solvency Score
Solvency Due Diligence
Bristol-Myers Squibb Co's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
Bristol-Myers Squibb Co's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BMY Price Targets Summary
Bristol-Myers Squibb Co
According to Wall Street analysts, the average 1-year price target for BMY is 57.07 USD with a low forecast of 40.4 USD and a high forecast of 78.75 USD.
Ownership
BMY Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
BMY Price
Bristol-Myers Squibb Co
Average Annual Return | 17.37% |
Standard Deviation of Annual Returns | 20.75% |
Max Drawdown | -40% |
Market Capitalization | 98.6B USD |
Shares Outstanding | 2 033 000 000 |
Percentage of Shares Shorted | 1.73% |
BMY News
Last Important Events
Bristol-Myers Squibb Co
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Bristol-Myers Squibb Co
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in New York City, New York and currently employs 32,200 full-time employees. The firm is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The firm offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. The Company’s pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company’s products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.
Contact
IPO
Employees
Officers
The intrinsic value of one BMY stock under the Base Case scenario is 74.86 USD.
Compared to the current market price of 48.79 USD, Bristol-Myers Squibb Co is Undervalued by 35%.